Attachment 1 PD_Waters_ACQUITY-SFC-QDa_PD_LC220201014023.pdf
PDF 1 MB Posted
- Solicitation number
- 75N95022Q00513
View the file
Other files
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Please wait...
If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.
For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.
Purchase Description Statement of Need and Purpose:
Background Information and Objective:
Generic Name of Product:
Purchase Description:
Salient Characteristics:
Quantity:
Delivery Date:
Period of Performance:
Option(s):
9.0.0.2.20101008.1.734229
| ResetButton1: |
| SaveAs: |
| Include a general narrative of the need of the requirement and the desired results.: This requisition is to purchase a Waters ACQUITY UltraPerformance C2 SFC instrument with QDa for the Analytical Chemistry Core (ACC) within the Division of Preclinical Innovation (DPI) at NCATS |
| Include a brief history of the requirement, the importance of the requirement, and the overall program objectives.: NCATS has become a key partner in the Antiviral Program for Pandemics (APP), a multi-agency initiative that includes NIAID and BARDA, to accelerate antiviral development through early discovery and preclinical development of safe and effective oral antivirals. The initial priority for the APP is to develop treatments for SARS-CoV-2 and other coronaviruses, with the program expanding to address other virus families with pandemic potential. NCATS will apply its proficiency in drug discovery and development and its cutting-edge technologies to fill critical needs of the APP, such as (i) target validation, (ii) high-throughput screening (HTS) for drug starting points, (iii) medicinal chemistry for lead optimization, and (iv) preclinical, investigational new drug (IND)-enabling development. APP chemists within DPI are tasked with the discovery and development potential small molecule antiviral treatments for a range of viruses that have pandemic potential. In order to meet the increased demand for sample purification and analysis, the Analytical Chemistry Core (ACC) needs to improve throughput and expand capabilities through procurement of additional instrumentation and equipment, as well as the application of new technologies. |
Of all the chromatographic techniques and methods that the ACC has available, supercritical fluid chromatography (SFC) is a technique that is not current employed for the analysis and purification of compounds synthesized by DPI medicinal chemists. SFC is a variant of normal-phase HPLC where supercritical CO2 is used as the mobile phase along with a cosolvent to modify polarity. The unique properties of the supercritical fluid enable chemical separations not readily possible with other chromatographic techniques. With the understanding that a limited number of chromatographic techniques cannot possibly purify all compounds, the ACC sees the incorporation of SFC into the SMART Centralized Sample Purification and Processing Platform as a means to expand purification capabilities and resolve operational issues. A bottleneck in the workflow is the removal of solvent after purification, which is a time-consuming process dependent on the volume and boiling point of the solvent. As we move to a more automated platform, a reduction in solvent removal time is needed to increase throughput and cycle time. SFC offers a convenient solution as CO2 is easily removed through rapid evaporation leaving behind pure material. An additional benefit of SFC is an increased sample load injection while still maintaining good separation efficiency enabling faster throughput or larger amounts of material. As such, the ACC is looking to expand its chromatography capabilities with the acquisition of a Waters ACQUITY UltraPerformance C2 SFC instrument with QDa for analytical analysis of compounds synthesized by APP, ETB, TDB, and CGB medicinal chemists within DPI.
| Specify the generic name of the component or system, e.g., freezer, microscope, cell sorter, etc.: Supercritical fluid chromatography (SFC) instrument with mass spectrometry detector |
| Specify 1) trade name; 2) product’s brand name; 3) manufacturer's name; 4) model, type, catalog, and/or part number(s.): Waters ACQUITY UltraPerformance C2 SFC instrument with QDa |
| Specify the significant, essential physical, functional, performance, or material element(s) (the distinguishing characteristic) of a product, system, component, or service required. Specify the functions that a system or component must perform to meet the Government’s objectives. Include required levels of performance, features or characteristics of the system or component that are essential to meet the government’s objectives. Specify the Government’s minimum acceptable standards.: The unique features of the Waters ACQUITY ACQUITY UltraPerformance C2 SFC instrument with QDa system are: |
1. 176815010 - ACQUITY UltraPerformance C2 System
With the following configuration:
a. 176015036 - ACQUITY UPC2 Core 2 CM-A + CM-AUX
b. 176015047 - ACQUITY UPC2 PDA Detector
c. 176002811 - UPC2 Standards Kit
d. 176003208 - ACQUITY QDa Detector (Performance)
e. 176003262 - Startup Kit, UPC2 and QDa System
f. 176003248 - ISM & UPC2 Triple Splitter Kit
g. 176015027 - ACQUITY UPLC ELSD w/Nebulizer
h. 176001060 - ML 4.1 & Standard PC
i. 668000273 - MONITOR, 23"
j. 741000473 - UPC² QDa INSTALLATION CERTIFICATE
k. 750000487 - NA – Professional Srv Training – 2 Days
2. 720002242EN - Implementation Kit
| Specify quantity. : One (1) each of all products listed in salient characteristics |
| Specify desired delivery date after receipt of order (30-60 days.): Thirty (30) days after receipt of the award |
| Specify period of performance for software license, warranty, or maintenance agreements.: One (1) twelve (12) month period of included manufacturer's warranty to begin after completion of instrument installation |
| Specify if options for additional quantities or options to extend the term of the contract for service agreements.: N/A |
File details come from the government source that posted it. Updated .